| pubmed-article:10198757 | pubmed:abstractText | The main components of bromantan central neurotropic effect is its dopamine-positive activity: antagonism (5 mg/kg) to the effects of neuroleptics in rats, blocking (50 microM) of dopamine synaptosomal capture, and a complicated in structure influence on the serotoninergic mediator systems--inhibition of neuronal capture of serotonin (50 microM), behavior responses to 5-hydroxytryptophan (1-20 mg/kg) in mice, decrease in the mediator content in intact rat brain when administered in doses lower than 5 mg/kg, and the absence of this parameter with the use of higher doses. The central noradrenergic effect of the drug is less expressed: blocking of the synaptosomal capture of norepinephrine in higher (more than 500 microM) concentrations), and absence of an effect, in distinction from sydnocarb, 1-5 mg/kg, on the mediator content in intact rat brain. The drug (1-50 mg/kg, intravenously) has no effect on neuro-muscular transmission in cats and in higher doses (30-600 mg/kg) inhibits to a certain degree the central effects of nicotine and arecoline. | lld:pubmed |
